CCM
CNCE

CAAS Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

CAAS Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,534
Closed -$49K – 1046
2022
Q2 		$49K Buy
+11,534
New +$45.6K ﹤0.01% 768

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAAS Capital Management's CNCE Position: Q3 2022 in Review

CAAS Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2022, closing a stake of 11,534 shares — an estimated $49K sold.

CAAS Capital Management first reported a position in CNCE in Q2 2022 and held it in 1 quarter. The position peaked at $49K in Q2 2022. 80 funds tracked by Wall St. Rank hold CNCE as of Q3 2022.

  • CAAS Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • CAAS Capital Management sold 11,534 Concert Pharmaceuticals, Inc. shares in Q3 2022, an estimated $49K.
  • CAAS Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2022 and held it in 1 quarter.
  • CAAS Capital Management's Concert Pharmaceuticals, Inc. position peaked at $49K in Q2 2022.
  • 80 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2022.

Based on CAAS Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.